A May 2026 study reported that GLP-1 medicines do not cause disproportionate loss of muscle mass or function, adding nuance to a common concern, though monitoring is still advised.
A March 2026 study (in Cell Reports Medicine) reported that GLP-1 medicines do not cause disproportionate loss of muscle mass or function during weight loss, adding nuance to a widely repeated concern. Experts still advise protein intake, resistance exercise, and monitoring during rapid weight loss.
A common worry about GLP-1 weight loss is that it strips away muscle along with fat. A May 2026 study added important nuance, reporting that GLP-1 medicines do not result in a disproportionate loss of muscle mass or function, that is, the muscle changes seen are in line with what is expected during weight loss generally, rather than a unique harm of the drugs.
This does not erase the topic. Some loss of lean mass accompanies most significant weight loss, and clinicians continue to emphasize adequate protein, resistance exercise, and monitoring, especially for older adults and during rapid weight reduction. But the finding pushes back on the strongest version of the "GLP-1s destroy muscle" claim and reframes it as a manageable aspect of weight loss rather than a reason to avoid treatment.
WHY IT MATTERS For consumers, this is reassuring context that also reinforces good practice: if you are losing weight on a GLP-1, attention to protein and strength training supports healthy body composition. As with all of this, individual circumstances vary, and body-composition concerns are worth discussing with a prescriber rather than acting on alarming headlines.